[« back]
Press Release 13.11.2008
mtm laboratories AG to present at BIO-Europe 2008 in Mannheim/Heidelberg
Heidelberg, Germany; November 13, 2008. mtm laboratories, a fully integrated cancer diagnostics company with proprietary products marketed globally, today announced that it will be presenting at BIO-Europe in Mannheim, Germany on 19 November 2008. The presentation by Bob Silverman, CEO of mtm laboratories, will include mtm?s biomarker-based diagnostic and screening products for the accurate diagnosis of cervical cancer, the largest existing screening market in oncology.
The biomarker that mtm uses in its screening and diagnostic products is the cyclin-dependent kinase inhibitor p16INK4a, the over-expression of which has been shown to be a highly specific marker of the onset of cervical cancer. It is crucial to a positive prognosis that cervical cancer is identified and treated as early as possible and p16INK4a as a biomarker makes such early accurate diagnoses possible.br>
BIO-Europe brings together international decision-makers from the biotechnology, pharmaceutical and financial sectors, offering networking opportunities, workshop participation, and private, pre-scheduled one-to-one meetings. Investment and collaboration opportunities developed in prior BIO- Europe conferences have produced many highly successful business partnerships.
mtm laboratories AG is an ISO 9001 and ISO 13485 certified developer and manufacturer of In-Vitro Diagnostic Devices (IVDD) for use in the early detection and diagnosis of cervical cancer. The Company operates on a global basis with the headquarter in Heidelberg, Germany and subsidiaries in the United States, France, Italy and Spain. Further information can be found at: www.mtmlabs.com.
Further Information:
Bob Silverman
CEO
mtm laboratories AG
Phone: +49 (0) 6453 64818-0
E-Mail: contact[at]mtmlabs.com
Dr. Douglas Pretsell
Account Director, Munich Bureau Chief
College Hill
Phone : +49 (0)89 57 00 18 06
E-Mail: douglas.pretsell[at]collegehill.com
Notes for editors:
The CINtec® family of diagnostic products
mtm's family of products is based on mtm's proprietary E6H4TM antibody clone which was specifically developed for immunochemistry applications in cervical histology and cytology specimens. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. The over-expression of this biomarker is directly correlated to the oncogenic activity of High Risk Human Papilloma Virus (HR-HPV) that marks the generation of cervical cancer. These biomarker-based diagnostic assays hold the promise to bring high levels of sensitivity and specificity towards the detection of high grade cervical disease in adjunctive uses with conventional technologies.
The CINtec® immunoassays are validated to provide a sensitive and specific method for the detection of p16INK4a in cervical tissues. The currently marketed CINtec® In-vitro Diagnostics (IVDs) have been developed for application on
Press Release 13.11.2008
mtm laboratories AG to present at BIO-Europe 2008 in Mannheim/Heidelberg
Heidelberg, Germany; November 13, 2008. mtm laboratories, a fully integrated cancer diagnostics company with proprietary products marketed globally, today announced that it will be presenting at BIO-Europe in Mannheim, Germany on 19 November 2008. The presentation by Bob Silverman, CEO of mtm laboratories, will include mtm?s biomarker-based diagnostic and screening products for the accurate diagnosis of cervical cancer, the largest existing screening market in oncology.
The biomarker that mtm uses in its screening and diagnostic products is the cyclin-dependent kinase inhibitor p16INK4a, the over-expression of which has been shown to be a highly specific marker of the onset of cervical cancer. It is crucial to a positive prognosis that cervical cancer is identified and treated as early as possible and p16INK4a as a biomarker makes such early accurate diagnoses possible.br>
BIO-Europe brings together international decision-makers from the biotechnology, pharmaceutical and financial sectors, offering networking opportunities, workshop participation, and private, pre-scheduled one-to-one meetings. Investment and collaboration opportunities developed in prior BIO- Europe conferences have produced many highly successful business partnerships.
mtm laboratories AG is an ISO 9001 and ISO 13485 certified developer and manufacturer of In-Vitro Diagnostic Devices (IVDD) for use in the early detection and diagnosis of cervical cancer. The Company operates on a global basis with the headquarter in Heidelberg, Germany and subsidiaries in the United States, France, Italy and Spain. Further information can be found at: www.mtmlabs.com.
Further Information:
Bob Silverman
CEO
mtm laboratories AG
Phone: +49 (0) 6453 64818-0
E-Mail: contact[at]mtmlabs.com
Dr. Douglas Pretsell
Account Director, Munich Bureau Chief
College Hill
Phone : +49 (0)89 57 00 18 06
E-Mail: douglas.pretsell[at]collegehill.com
Notes for editors:
The CINtec® family of diagnostic products
mtm's family of products is based on mtm's proprietary E6H4TM antibody clone which was specifically developed for immunochemistry applications in cervical histology and cytology specimens. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. The over-expression of this biomarker is directly correlated to the oncogenic activity of High Risk Human Papilloma Virus (HR-HPV) that marks the generation of cervical cancer. These biomarker-based diagnostic assays hold the promise to bring high levels of sensitivity and specificity towards the detection of high grade cervical disease in adjunctive uses with conventional technologies.
The CINtec® immunoassays are validated to provide a sensitive and specific method for the detection of p16INK4a in cervical tissues. The currently marketed CINtec® In-vitro Diagnostics (IVDs) have been developed for application on
- cervical biopsies (CINtec® Histology) and
- cervical cytology preparations such as smears and liquid based cytology samples (CINtec® Cytology)
CINtec® products are available on a global basis through mtm's direct operations and distributors.
® mtm laboratories AG, all rights reserved